China Pituitary Disease Registry (CAPASITY)
China Pituitary Disease Registry (CAPASITY)
Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary
 disease and related mortality worldwide. In order to meet all the challenges in the treatment
 of pituitary disease in China, CAPASITY was founded in 2020. The objective of CAPASITY is to
 launch a pituitary disease management model based on the Internet health information
 platform. It allows the application and evaluation of pituitary disease treatment strategies
 at multiple centers. The proprietary electronic medical database will help the dynamic
 big-data analysis in epidemiology of pituitary disease, diagnosis, and treatment.
In order to meet all the challenges in the diagnosis and treatment of pituitary diseases in
 China, CAPASITY was founded in 2020. With advanced medical equipment and Internet of Things
 (IoT) technology, CAPASITY is committed to creating an online and offline integrated solution
 for pituitary disease, and for the entire spectrum of pituitary disease, to achieve a more
 convenient and precise model of care for patients. aiming to establish a platform with
 diagnosis and treatment of pituitary disease and their long-term follow-up. It allows the
 application and evaluation of treatment strategies at these centers.

 Objective:

 -  The purpose of the present study is to establish a multi-center nationwide prospective
 database of patients with pituitary adenomas to explore the epidemiology, biochemical,
 and clinical outcome related to pituitary tumors and its complications, as well as other
 pituitary disease.

 -  To collect cross-sectional data from patients seen and treated at each center so as to
 evaluate: the current status of care of patients with pituitary disease and its related
 complications, as well as other risk factors treatment strategies at multiple centers.

 -  To collect the prospective data of patients treated at each center in order to evaluate
 the strategies for the achievement of treatment goals, changes in management, control of
 risk factors, incidence and progression of related clinical endpoints (including
 mortality), behavioral changes, as well as QoL.

 Methods: After obtaining informed consent, patients will be invited and initiated with a
 comprehensive baseline evaluation at each CAPASITY center. Then patients will be followed by
 clinical/laboratory visits on according to individualized patient's treatment plans. A
 repeated comprehensive clinical and laboratory assessment for hormones and imaging, as well
 as complications will be scheduled once a year.
Inclusion Criteria:

 -  Age ≥ 18 years old and ≤ 75 years

 -  Patients diagnosed with pituitary adenomas, and other pituitary diseases

 -  Pituitary adenomas resected by transsphenoidal surgery were identified by histological
 diagnoses.

 -  Gender: males and females

 -  Provide written informed consent

 -  Satisfactory compliance

 Exclusion Criteria:

 -  Patients with significantly reduced life expectancy (less than 2 years)

 -  With Drug abuse

 -  With AIDS or syphilis or infectious diseases such as viral tuberculosis in active
 phase at enrollment